Evidence map›Paper›PMID 31022994›Full record

ReviewInternational journal of stem cells2019

Mesenchymal Stem Cells from the Wharton's Jelly of the Human Umbilical Cord: Biological Properties and Therapeutic Potential.

Luigi Marino, Maria Antonietta Castaldi, Rosa Rosamilio, Enrico Ragni, Rosa Vitolo, Caterina Fulgione, Salvatore Giovanni Castaldi, Bianca Serio, Rosario Bianco, Maurizio Guida and 1 more

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of stem cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 1 pooled it
12.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 1 synthesis or guideline pooled it, 162 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. [Research advances in mesenchymal stem cell therapy for graft-versus-host disease].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Hepatoprotective effect of hUC-MSC secretome in LPS-induced HepG2 cells.Iranian journal of basic medical sciences · 2026
    Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Luigi MarinoDepartment of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy.
Maria Antonietta CastaldiDepartment of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy.
Rosa RosamilioDepartment of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy.
Enrico RagniOrthopedic Biotechnology Laboratory, Galeazzi Orthopedic Institute, Milan, Italy.
Rosa VitoloDepartment of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy.
Caterina FulgioneDepartment of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy.
Salvatore Giovanni CastaldiDepartment of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy.
Bianca SerioDepartment of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy.
Rosario BiancoDepartment of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy.
Maurizio GuidaDepartment of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy.
Carmine SelleriDepartment of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy.
University of Salerno · ITAzienda di Rilievo Nazionale ed Alta Specializzazione · ITIstituto Ortopedico Galeazzi · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Wharton's jelly mesenchymal stem cells (WJ-MSCs) are a class of stem cells with high differentiative potential, an immuno-privileged status and easy access for collection, which raise no legal or ethical issues. WJ-MSCs exhibit several features of embryonic stem cells, both in the phenotypic and genetic aspects, with only a few differences, such as a shorter doubling time and a more extensive ex vivo expansion capacity. WJ-MSCs have immunomodulatory properties, involving both innate and adaptive immune responses. This review focuses on the role of WJ-MSCs in the management of graft-versus-host disease (GvHD), a life-threatening complication of the allogenic transplantation of hematopoietic stem cells. Different studies documented the beneficial effect of the infusion of WJ-MSCs, even when not fully HLA identical, in patients with severe GvHD, refractory to standard treatment. Finally, we summarized current ongoing clinical trials with WJ-MSCs and their potential in regenerative medicine.

Indexed as

GvHDHuman umbilical cord bloodImmunomodulationMesenchymal stem cellsWJ-MSCs

Identifiers

PMID31022994
PMCPMC6657936
OpenAlexW2941661312

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.